Stroke Prevention in Sickle Cell Anemia (STOP 1)
Launched by AUGUSTA UNIVERSITY · Oct 27, 1999
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
Stroke, occurring in about 10 percent of pediatric patients with sickle cell disease, is one of the most devastating complications, with a high recurrence rate after the first episode. Several non-randomized studies have shown reduction in stroke recurrence when periodic blood transfusions are administered to maintain hemoglobin S under 30 percent. Periodic blood transfusions are associated with significant risks of iron overload and other complications and must be accompanied by parenteral iron chelation therapy. However, this has become a standard of care for prevention of re...
Gender
ALL
Eligibility criteria
- • Pediatric patients, ages 24 months to 16 years, with sickle cell anemia or S-beta zero thalassemia.
About Augusta University
Augusta University is a prominent academic institution dedicated to advancing healthcare through innovative research and clinical trials. As a leader in medical education and patient care, Augusta University conducts rigorous clinical studies aimed at improving treatment outcomes and enhancing patient quality of life. The university’s commitment to interdisciplinary collaboration fosters a dynamic research environment, enabling the exploration of novel therapies and interventions across a wide range of medical fields. With a focus on ethical standards and patient safety, Augusta University strives to translate scientific discoveries into tangible benefits for the community and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Donald Brambilla
New England Research Institute Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials